Filing Flows › Health Care › Mangoceuticals (MGRX)
Mangoceuticals (MGRX) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Mangoceuticals (MGRX) Q2 2026 earnings results →
Q2 2026 Revenue down 59% year over year to $69K
Mangoceuticals made $69K in Q2 2026 (-59% Y/Y). Operating margin n/m, net loss $1.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $69K in Q2 2026, down 59% year over year and up 1% from the previous quarter.
Gross margin was 64.3%, up 10.8 points from Q2 2025. Operating costs exceeded revenue by $1.0M, an operating margin of -1502.5%. Operating expenses fell 80% while revenue fell 59%. The fastest-growing cost line was Sales & marketing (+17%). The quarter ended with a net loss of $1.3M, narrower than the previous quarter's $3.4M loss. Minority interests bore $0K of it: to shareholders the quarter was a loss of $1.3M.
Operating cash flow was −$261K. Non-cash charges added back $280K of depreciation and amortization and $12K of share-based compensation. Working capital and other items added $760K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $69K | -59% | n/m | −$1.3M | −$261K |
| Q1 2026 | 10-Q | May 19, 2026 | $68K | -38% | n/m | −$3.4M | −$1.3M |
| Q4 2025 | 10-K | Apr 1, 2026 | $94K | -10% | -389.7% | −$2.8M | −$1.1M |
| Q3 2025 | 10-Q | Nov 14, 2025 | $84K | -37% | n/m | −$7.6M | −$1.2M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $168K | +3% | n/m | −$5.4M | −$1.3M |
| Q1 2025 | 10-Q | May 15, 2025 | $109K | -49% | n/m | −$4.8M | −$2.3M |
| Q4 2024 | 10-K | Mar 20, 2025 | $105K | -57% | n/m | −$1.9M | −$1.1M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Mangoceuticals
The information included in this Report on Form 10-K should be read in conjunction with the consolidated financial statements and related notes in “ Item 8. Financial Statements and Supplemental Data ” of this Report. Our logo and some of our trademarks and tradenames are used in this Report. This Report also includes trademarks, tradenames and service marks that are the property of others. Solely for convenience, trademarks, tradenames, and service marks referred to in this Report may appear without the ®, ™ and SM symbols.
In its own words, from its 10-K, filed Apr 1, 2026.
Mangoceuticals against its Services-Misc Health & Allied Services, NEC peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -59% against the peers' median +5%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| MGRX Mangoceuticals | Q2 2026 | $69K | -59% | n/m |
| DVA Davita | Q3 2026 | $3.6B | +5% | 14.0% |
| AGL agilon health | Q3 2026 | $1.5B | +6% | 1.6% |
| PGNY Progyny | Q3 2026 | $341M | +9% | 10.3% |
| SHC Sotera Health | Q3 2026 | $325M | +4% | 25.8% |
| VMD Viemed Healthcare | Q3 2026 | $80.7M | +12% | 8.6% |
| PARK Park Dental Partners | Q2 2026 | $66.2M | +5% | 1.9% |
| CCEL Cryo Cell International | Q3 FY26 | $7.8M | 0% | 28.0% |
| MRAI Marpai | Q2 2026 | $4.2M | -10% | -82.4% |
Source: Mangoceuticals 10-Q on SEC EDGAR · CIK 1938046 · Services-Misc Health & Allied Services, NEC
13F: who owns MGRX and who is buying
More on MGRX
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results